Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity

다국어 초록 (Multilingual Abstract)

The RNA-binding protein tristetraprolin (TTP) binds to adenosine- uridine AU-rich elements in the 3’-untranslated region of messenger RNAs and facilitates rapid degradation of the target mRNAs. Therefore, it regulates the expression of multiple cancer and immunity-associated transcripts. Furthermore, a lack of TTP in cancer cells influences cancer progression and predicts poor survival. Although the functions of TTP on cancer cells have previously been researched, the mechanism of TTP on the interaction between cancer cells with their microenvironment remains undiscovered. In this study, we admed to determine the role of cancer cell TTP during the interaction between tumor and immune cells, specifically regulatory T cells (Tregs). We evaluate the capability of TTP to modulate the antitumor immunity of GC and explored the underlying mechanism. The overexpression of TTP in GC cells dramatically increased peripheral blood mononuclear lymphocyte (PBML) -mediated cytotoxicity against GC cells. Increased cytotoxicity against TTP-overexpressed GC cells by PBMLs was determined by Treg development and infiltration. Surprisingly, we found the stabilization of programmed death-ligand 1 (PD-L1) mRNA was declining while TTP was elevated. The PDL1 protein level was reduced in TTP-abundant GC cells. PD-L1 gas been found to play a pivotal role in Treg development and functional maintenance in immune system. Taken together, our results suggest the overexpression of TTP in GC cells not only affects cell survival and apoptosis but also increases PBMLs -mediated cytotoxicity against GC cells to decelerate tumor progression. Moreover, we identified PD-L1 as a critical TTP-regulated factor that contributes to inhibiting antitumor immunity.

참고문헌 (Reference)

1 Friedl, P., "Tumour-cell invasion and migration: diversity and escape mechanisms" 3 : 362-374, 2003

2 Deng, K., "Tristetraprolin inhibits gastric cancer progression through suppression of IL-33" 6 : 24505-, 2016

3 Zeng, B., "Tristetraprolin exerts tumor suppressive functions on the tumorigenesis of glioma by targeting IL-13" 39 : 63-70, 2016

4 Brooks, S.A., "Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action" 1829 : 666-679, 2013

5 Sanduja, S., "The roles of TTP and BRF proteins in regulated mRNA decay" 2 : 42-57, 2011

6 Sanduja, S., "The role of tristetraprolin in cancer and inflammation" 17 : 174-188, 2012

7 Guo, J., "The role of RNA-binding protein tristetraprolin in cancer and immunity" 34 : 196-, 2017

8 Giraldo, N.A., "The immune contexture of primary and metastatic human tumours" 27 : 8-15, 2014

9 Guo, J., "The cross-talk between tristetraprolin and cytokines in cancer" 17 : 1477-1486, 2017

10 Zhang, M., "The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients" 6 : 37933-, 2016

11 Tian, M., "The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats" 6 : 27683-, 2016

12 Pollack, S.M., "T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas" 2017

13 Curiel, T.J., "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival" 10 : 942-949, 2004

14 Tripathi, S., "Role of PD1/PDL1 pathway, and TH17 and treg cells in maternal tolerance to the fetus" 38 : 25-31, 2015

15 Jeltsch, K.M., "Regulation of T cell signaling and autoimmunity by RNA-binding proteins" 39 : 127-135, 2016

16 Hirai, M., "Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment" 50 : 41-48, 2017

17 Newman, R., "RNA binding proteins as regulators of immune cell biology" 183 : 37-49, 2016

18 Yuan, J., "Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance" 7 : 39671-39679, 2016

19 Cho, J., "Programmed cell deathligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability" 8 : 13320-13328, 2017

20 Liu, H., "PD-L1 signal on liver dendritic cells is critical for Foxp3(+)CD4(+)CD25(+) Treg and liver tolerance induction in mice" 45 : 1853-1855, 2013

21 Peligero, C., "PD-L1 blockade differentially impacts regulatory T cells from HIV-infected individuals depending on plasma viremia" 11 : e1005270-, 2015

22 Li, Z., "PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell infiltration of breast cancer and poor prognosis of patient" 7 : 784-793, 2016

23 Ai, R., "Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy" 8 : 81617-81635, 2017

24 Mohamed, M.S., "Inhibitors of apoptosis: clinical implications in cancer" 22 : 1487-1509, 2017

25 Junttila, M.R., "Influence of tumour micro-environment heterogeneity on therapeutic response" 501 : 346-354, 2013

26 Liu, C., "Increased expression of PDL1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity" 15 : 1063-1070, 2017

27 Hatam, L.J., "Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression" 18 : 1925-1935, 2012

28 Finn, O.J., "Human tumor antigens yesterday, today, and tomorrow" 5 : 347-354, 2017

29 Tan, M.P., "Human leucocyte antigen class I-redirected anti-tumour CD4(+) T cells require a higher T cell receptor binding affinity for optimal activity than CD8(+) T cells" 187 : 124-137, 2017

30 Heeren, A.M., "High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer" 3 : 48-58, 2015

31 Seo, G.S., "Heme oxygenase-1 promotes tumor progression and metastasis of colorectal carcinoma cells by inhibiting antitumor immunity" 6 : 19792-19806, 2015

32 Yuan, X.L., "Gastric cancer cells induce human CD4+Foxp3+ regulatory T cells through the production of TGF-beta1" 17 : 2019-2027, 2011

33 Iovanna, J.L., "Factors released by the tumor far microenvironment are decisive for pancreatic adenocarcinoma development and progression" 6 : e1358840-, 2017

34 Geng, Y., "Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance" 20 : 273-281, 2015

35 Das, S., "Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection" 176 : 3000-3009, 2006

36 Perez-Ortin, J.E., "Eukaryotic mRNA decay: methodologies, pathways, and links to other stages of gene expression" 425 : 3750-3775, 2013

37 Milke, L., "Depletion of tristetraprolin in breast cancer cells increases interleukin-16 expression and promotes tumor infiltration with monocytes/macrophages" 34 : 850-857, 2013

38 Zheng, X.T., "Corrigendum to "Sodium butyrate down-regulates tristetraprolin-mediated cyclin B1expression independent of the formation of processing bodies" [Int. J. Biochem. Cell Biol. 69 (2015) 241-248]" 74 : 161-, 2016

39 Hou, J., "Correlation between infiltration of $FOXP^{3+}$ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer" 96 : 284-291, 2014

40 Eckert, A.W., "Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma" 14 : 85-, 2016

41 Siegel, R., "Cancer statistics, 2012" 62 : 10-29, 2012

42 Schreiber, R.D., "Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion" 331 : 1565-1570, 2011

43 Becht, E., "Cancer immune contexture and immunotherapy" 39 : 7-13, 2016

44 Robert, J., "Biology of cancer metastasis" 100 : 333-342, 2013

45 Liu, X., "Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer" 9 : 853-860, 2016

46 Kataoka, K., "Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers" 534 : 402-406, 2016